The human cytochrome P450 (CYP) superfamily contributes to the metabolism of a variety of xenobiotics including therapeutic drugs, carcinogens, steroids and eicosanoids. 1) Recently, several reports have demonstrated that natural compounds and herbal products may cause a pharmacokinetic interaction with western drugs used clinically when they are simultaneously administered.
In our previous studies, we examined the inhibitory activity of some Indonesian medicinal plants against CYP3A4 and CYP2D6 5) and isolated (2R,3S,5R)-2,3-epoxy-6,9-humuladien-5-ol-8-one (1), (2R,3R,5R)-2,3-epoxy-6,9-humuladien-5-ol-8-one (2), (5R)-2,6,9-humulatrien-5-ol-8-one (3), kaempferol-3-O-(2,3-di-O-acetyl-a -L-rhamnopyranoside) (4), kaempferol-3-O-(2,3,4-tri-O-acetyl-a-L-rhamnopyranoside) (5), zerumbone (6) , zerumbone epoxide (7), kaempferol-3-O-(2,4-di-O-acetyl-a -L-rhamnopyranoside) (8) , kaempferol-3-O-(3,4-di-O-acetyl-a-L-rhamnopyranoside) (9) , kaempferol-3-O-(2-O-acetyl-a-L-rhamnopyranoside) (10), kaempferol-3-O-(3-O-acetyl-a-L-rhamnopyranoside) (11) , kaempferol-3-O-(4-O-acetyl-a-L-rhamnopyranoside) (12) , kaempferol-3-O-methyl ether (13) , kaempferol-3,4Ј-di-O-methyl ether (14) , (S)-6-gingerol (15) , and trans-6-shogaol (16) (Chart 1) from Zingiber aromaticum as inhibitors against the CYP3A4-mediated metabolism. In addition, compounds 5, 9, 13, and 14 also showed inhibitory activity to the metabolism by CYP2D6. 6 ) Z. aromaticum is one of the popular traditional medicines extensively used in Indonesia, 7, 8) and thus it is important to determine the possibility of mechanism-based inactivation on CYP3A4 and CYP2D6 by these compounds. In this report, we have performed kinetic analyses to investigate the mechanism-based inhibition of CYP3A4 and CYP2D6 by these compounds. , oxidized form), glucose-6-phosphate (G-6-P), and G-6-P dehydrogenase were purchased from Oriental Yeast Co., Ltd. (Tokyo, Japan). All other chemicals and solvents were of the highest grade available.
MATERIALS AND METHODS

Chemicals
Preparation of Test Solutions All the samples used in this experiment were isolated as described in the previous 6) For studies of time-and concentration-dependent inhibitions, various concentrations of sample (0-200 mM) according to the previous concentration-dependent assay and IC 50 data, 6) which dissolved in MeOH (final concentration of MeOH was 1%) were added to the incubation mixture containing 150 ml of phosphate buffer (0.1 M, pH 7.4), 197.5 ml of ultrapure water, and 50 ml of HLM (4 mg/ml). After 5 min preincubation under shaking at 37°C, the reaction was initiated by addition of 50 ml of NADPHgenerating system (4.20 mg/ml of NADP ϩ , 100 mM of G-6-P, 100 mM of MgCl 2 , and 10 U/ml of G-6-P dehydrogenase). At certain intervals, 50 ml of substrate was added and incubation was continued for 10 min (CYP3A4) or 20 min (CYP2D6) under the same conditions. The reaction was stopped by the addition of 125 ml of 10% trichloroacetic acid and CYP activity was assayed. An equivalent volume of MeOH was treated similarly as control. The inhibitory effect of samples was assessed from difference between the sample and corresponding control.
Time-and NADPH-Dependent Inhibition Assay Samples of a certain dose were preincubated with phosphate buffer (0.1 M, pH 7.4) and HLM (4 mg/ml) in the presence or absence of the NADPH-generating system (as described above). At various times (0, 5, 10, 20 min), 50 ml of substrate and 50 ml of NADPH-generating system were added and incubation was continued for 10 min (CYP3A4) or 20 min (CYP2D6) under the same conditions. The reaction was stopped by the addition of 125 ml of 10% trichloroacetic acid and CYP activity was assayed. Activities were normalized to the activity at 0 min so that the percent decrease in CYP activity reflected activity loss due only to inactivation and not reversible inhibition.
Analysis of Results
The logarithm of the remaining activities were plotted against incubation times and the slopes of these lines were obtained from linear regression analysis. The inactivation constants (k app ) were determined by multiplication of the resulting slopes by 2.303. The inactivation rate constant at an infinite concentration of inhibitor (k inact ) and the inhibitor concentration required for a half-maximal rate of inactivation (K I ) values were calculated from the double reciprocal plots of k app versus sample concentration by linear regression analyses using the software product WinNonlin Ver. 3.1 (Pharsight Corp., Mountain View, CA, U.S.A.). The y-intercept is known to equal 1/k inact while the x-intercept equals Ϫ1/K I .
RESULTS AND DISCUSSION
Metabolism by CYP represents the rate-limiting step in the metabolism of a large number of drugs; hence, inhibition of CYP is recognized as an important cause of drug interactions by the United States Food and Drug Administration (FDA) and other regulatory agencies. 9) Inhibitory drug interactions can cause symptoms of drug overdose, including an exaggerated pharmacological response and/or drug toxicity. These interactions generally fall into two categories. The first involves "direct" inhibition of the metabolism of one drug by the other. Direct inhibition may exhibit Michaelis-Menten kinetics characteristic of competitive, noncompetitive, uncompetitive, or mixed (competitive and noncompetitive) inhibition. The second type of drug interaction results from "irreversible" (or "quasi-irreversible") inhibition of CYP and often involves metabolism-dependent inhibition or suicide inactivation of CYP. This type of inhibition can completely block the metabolism of other drugs. 9) In a previous paper, we reported 16 compounds to be CYP3A4 inhibitory constituents of Z. aromaticum, which showed concentration-dependent CYP3A4 inhibition with an IC 50 value of 102 mg/ml. 5) Thus, we have examined the possibility of their mechanism-based inhibition. All compounds except for zerumbone (6) decreased the rate of metabolism mediated by CYP3A4 in both concentration-and time-dependent manners (Fig. 1) . Furthermore, in the NADPH-dependent assay of metabolism mediated by CYP3A4, compounds 1, 3, and 7 showed only 4.8, 6.3, and 0.9% decrease by incubation with NADPH for 20 min, while other compounds decreased by 26-82% (Fig. 2) . Thus, compounds 2, 4, 5, 8-16 showed NADPH-dependent inhibition, but others did not.
Pseudo-first-order kinetics was observed on the inactivation of the enzyme activity. The inactivation rate constant at an infinite concentration of inactivator (k inact ) and the concentration of inactivator required for a half-maximal rate of inactivation (K I ) were determined from double-reciprocal plots of k app values and inactivator concentrations.
10) Based on time-, concentration-, and NADPH-dependent inactivation kinetics, all seven kaempferol glycosides and two kaempferol derivatives (4, 5, 8-14) appear to be the mechanism-based inhibitors for CYP3A4. K I values for these compounds were in the range of 2.21-27.01 mM, whereas they had k inact values of 0.23-0.65 min Ϫ1 (Table 1) . Kaempferol-3-O-(2,3,4-tri-Oacetyl-a-L-rhamnopyranoside) (5), the most potent CYP3A4 inhibitor (IC 50 , 14.4 mM), 6) was found to be the most potent CYP3A4 inactivator with K I and k inact values of 2.21 mM and 0.45 min
Ϫ1
, respectively. On the humulene-type sesquiterpenes (1-3, 6, 7) , only 2 showed time-, concentration-and NADPH-dependent inactivation of CYP3A4. However, in the NADPH-dependent assay of 2 (Fig. 2, Table 1 ), a significant fraction of CYP3A4 activity (approximately 66%) remained after a 20 min preincubation with 2 (at 50 mM). Since in the previous concentration-dependent inhibition assay only 51% of CYP3A4 activity remained after incubation with 2 in the same dose, most of the inhibition by 2 may be reversible. 11) Similarly, in the NADPH-dependent assay, compounds 15 and 16 showed remaining CYP3A4 activity of 70 and 49% after 20 min preincubation, respectively (Table 1) , while in the concentrationdependent inhibition assay, they showed 60 and 42% of CYP3A4 activity remaining, respectively, suggesting that most inhibition of 15 and 16 may also be reversible.
For the CYP2D6 inhibition, only kaempferol-3-O-methyl ether (13) and kaempferol-3,4Ј-di-O-methyl ether (14) showed time-, concentration-, and NADPH-dependent inhibi-tion. By comparing the remaining activities in the NADPHdependent assay (13, 71%; 14, 79%) and those in concentration-dependent studies (13, 66%; 14, 76%), however, most of their inhibition seemed to be reversible. These data should suggest that interactions between the CYP3A4 substrates and 2, 15, or 16 and between the CYP2D6 substrates and 13 or 14 likely require the presence of both the substrates and inactivator. Thus, inhibition of these compounds may be of importance only when drugs and these compounds are administered concomitantly.
Previously, mechanism-based inhibition of some plant constituents were reported. 10, [12] [13] [14] [15] For example, Tassaneeyakul et al. reported bergamottin, 6Ј,7Ј-dihydroxybergamottin (DHB), GF-I-1, and GF-I-4, four furanocoumarins isolated from grapefruit juice were mechanism-based inhibitors of CYP3A4. 10) Resveratrol, a red wine constituent, and (Ϫ)-hydrastine, an alkaloid isolated from Hydrastis canadensis, also showed mechanism-based inhibition against CYP3A4. 12, 13) However, this is the first report about mechanism-based inhibition of kaempferol glycosides or kaempferol derivatives.
In conclusion, these results have demonstrated that all kaempferol glycosides with acetyl group in their structures and two kaempferol derivatives isolated from Z. aromaticum Preincubation with CYP3A4 or CYP2D6 was done at 37°C, ϩ/Ϫ NADPH for 0, 5, 10, and 20 min. In order to determine the extent of inactivation, CYP3A4 or CYP2D6 activity was normalized by the activity observed at 0 min, which was arbitrarily set as 100%. Each point represents the mean of duplicate determinations.
can cause mechanism-based inhibition of CYP3A4. 
